Guilherme Perini, MD
2.7K posts
@GuiperiniMD
Hematologist in Sao Paulo, Brazil. Focus on Lymphomas and CLL Host: Fase 3 Podcast Host: Happy Auer Podcast
If you have never come to @LymphomaEx you should do it. The energy is different. Great science. Even greater vibe. Little Lugano (Luganito) is the way.
Finishing the @LymphomaEx conference with an impromptu late night karaoke session by the lake. Thanks @GuiperiniMD for the brilliant idea of bringing a portable karaoke machine! @fabiopss @laura_korin @iHematologo @nico30f @cytohance
As BsAbs move into earlier lines, infection risk is the elephant in the room! Kim et al. @BloodAdvances: 75% cumulative infection rate at 24 mo. Neutropenia and low IgG drove risk, early steroids did not. IgG monitoring and timely IVIG remain key! doi.org/10.1182/blooda…
In the US we argue CAR-T vs bispecifics while 36% of Latin America fights for access to rituximab. Let that sink in. GELL Survey 2025 — 73 centers, 16 countries: 73% highly restricted access to bispecifics ~0% commercial CAR-T outside Brazil Only 15% have NGS Only 35% access to clinical trials We’re having 2026 debates with early 2000s access. The real question isn’t CAR-T vs bispecifics. It’s: how do we close this gap? Sobering data presented by @DrMCanales here in Chile. @LymphomaEx Colunga-Pedraza et al. Blood 2025;146(Suppl 1):6193 #Lymphoma #DLBCL #LATAM #GlobalOncology #HealthEquity
Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk onlinelibrary.wiley.com/doi/abs/10.100…
Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm
🧠 New phase II study in newly dx PCNSL: R-MVP + ibrutinib n=30, median age 69 CR/CRu 97% (29/30) with no refractory disease 25-mo f/u, median PFS/OS NR; 2-yr PFS 84% Toxicity manageable (cytopenias); no Aspergillus or PJP
